Develops retinal disease medicines for patients with retinal vascular diseases and macular edema caused by inflammation.
10-K for FY2025, filed Mar 31, 2026Since its founding in 2009, Kodiak Sciences Inc. (“Kodiak,” the “Company,” “we” or “our”) has developed a new technology platform, the…View ↗
Kodiak’s second investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC…View ↗
Kodiak’s third investigational medicine, KSI-101, is a high strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF. We are…View ↗
No revenue reported yet.
10-K for FY2025, filed Mar 31, 2026
The candidates target patients with diabetic retinopathy, wet AMD and retinal vein occlusion, as well as macular edema caused by inflammation.
10-K for FY2025, filed Mar 31, 2026
10-Q for Q3 FY2026, filed Nov 12, 2026
−$66.2MView ↗
8-K, filed Nov 12, 2026
On November 12, 2026, Kodiak Sciences Inc. (the “Company”) published a press release reporting the Company’s financial results for the…View ↗
8-K, filed Sep 28, 2026
On September 28, 2026, Kodiak Sciences Inc. (the “Company”) issued a press release announcing that the primary endpoints were met for both…View ↗
A new inflammation-focused program
The older report described retinal vascular medicines and triplet medicines for dry AMD and glaucoma; the latest adds a candidate for macular edema caused by inflammation.
10-K for FY2022, filed Mar 28, 2023 10-K for FY2025, filed Mar 31, 2026Kodiak’s lead product candidate, tarcocimab tedromer (“KSI-301” or “tarcocimab”), has been advanced into six registrational clinical…View ↗
In addition, Kodiak is investing in its pipeline. The Company is progressing its Antibody Biopolymer Conjugate (“ABC”) PlatformTM towards…View ↗
In 2022, we broadened our development pipeline of product candidates built on our ABC Platform with the filing of the Investigational New…View ↗
Kodiak’s third investigational medicine, KSI-101, is a high strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF. We are…View ↗
Competes with Avastin, Eylea, Eylea HD, Vabysmo, Lucentis, Roche, and Regeneron
10-K for FY2025, filed Mar 31, 2026The current standard of care for DR (including DME), RVO and wet AMD consists of intravitreal administration of anti-VEGF therapies.…View ↗
Loading...